Comparative Analysis of Niosomal Mefloquine and Cisplatin on Apoptosis

Overview

Revise to specify how the study enhances therapeutic efficacy and the distinct pathways targeted.

Background

Breast cancer remains a leading cause of cancer-related mortality among women, with triple-negative breast cancer (TNBC) posing significant treatment challenges due to its aggressive nature and high rates of metastasis. Current therapies often face limitations due to drug resistance, making the exploration of novel combination strategies essential for improving patient outcomes.

Data Highlights

No numerical data available in the source material.

Key Findings

• Niosomal mefloquine targets lysosomal and mitochondrial pathways to induce apoptosis in breast cancer cells.
• Cisplatin promotes apoptosis through DNA cross-linking but is often limited by acquired resistance mechanisms.
• Combining mefloquine and cisplatin may synergistically enhance anti-cancer effects by addressing different resistance pathways.
• Mefloquine exhibits anti-angiogenic properties by impairing VEGF signaling, which is crucial for tumor growth and metastasis.
• Utilizing niosomes for drug delivery can improve the efficacy of anticancer agents while minimizing side effects.

Clinical Implications

The findings support the potential of combining niosomal mefloquine with cisplatin as a strategy to overcome resistance in breast cancer treatment. Clinicians may consider this combination to enhance therapeutic outcomes, particularly in patients with TNBC.

Conclusion

The study highlights the promise of integrating niosomal mefloquine with cisplatin to improve apoptosis and inhibit angiogenesis in breast cancer, warranting further investigation in clinical settings.

References

1. Archives of Toxicology, 2024 -- Cisplatin-Conjugated Carbon Nanotubes Induce Distinct Apoptotic Signaling Pathways in 2D and 3D Spheroid Cultures of Triple-Negative Breast Cancer Cells: A Comparative Analysis
2. Gastric Cancer, 2024 -- Functional genomics uncovers a non-specific reliance on drug combination effects in the treatment of gastric cancer
3. Archives of Toxicology, 2020 -- In Vitro Evaluation of Myricetin in Bulk and Nanoparticle Forms for Anticancer Activity in Lymphocytes from Multiple Myeloma Patients
4. NCCN 2026 Breast Cancer Congress_Neo-Adj -- Clinical Practice Guidelines
5. Archives of Toxicology — Discovery of Potential New Mechanisms of Drug Resistance Through Genomic and Transcriptomic Analysis of Colon Cancer Cells Lacking p53
6. NCCN 2026 Breast Cancer Congress_Neo-Adj
7. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis - PubMed
8. Withdrawn | Cancer Accelerated Approvals | FDA